Key Principles
The guidance establishes a predictable and efficient framework for formal interactions between the FDA and sponsors. Its core principle is that timely, high-quality communication is critical to a streamlined drug development process. The document clarifies that different stages of development require different types of meetings (e.g., Type A, B, and C), each with specific timelines and objectives. A key principle is that productive meetings depend on the sponsor providing a comprehensive meeting package in advance, allowing the FDA to prepare and provide substantive feedback.

Recommendations for Sponsors
Sponsors are strongly recommended to engage with the FDA early and throughout the drug development process. To ensure a productive meeting, sponsors should clearly articulate the purpose of the meeting, provide specific questions, and submit a well-organized and complete meeting package by the specified deadline. It is recommended that sponsors carefully consider the type of meeting that is most appropriate for their stage of development and the nature of the questions they have. Following the meeting, sponsors should adhere to the timelines and procedures for submitting meeting minutes for the official record.

Regulatory Considerations
This guidance is a key component of the regulatory framework under the Prescription Drug User Fee Act (PDUFA). Adherence to the procedures outlined in this document is a matter of regulatory compliance. The formal meetings described are a critical part of the Investigational New Drug (IND) and Marketing Authorization Application processes. The meeting process is designed to provide regulatory clarity, reduce the risk of clinical holds or refuse-to-file actions, and ultimately support a more efficient and predictable path to drug approval. The written record of these meetings serves as an important part of the administrative file for a product’s development program.